Clec18a Antibody

What is CLEC18A and what are its primary functions in the immune system?

CLEC18A is a C-type lectin protein that is ubiquitously expressed in humans, with highest expression levels observed in myeloid cells and liver tissue. The protein functions as a co-receptor for Toll-like receptor 3 (TLR3) in endosomes, where it binds specifically to poly(I:C) and enhances the production of type I and type III interferons in response to viral challenges such as H5N1 influenza A virus (IAV) infection . Interestingly, mouse CLEC18A (mCLEC18A) shows a different tissue distribution pattern, being primarily expressed in brain, kidney, and heart tissues, which may contribute to differential immune responses between humans and mice .

The protein's structural features include a critical amino acid at position 339, where a single amino acid change (S339→R339) in the CTLD domain significantly affects binding capacity to polysaccharides and various allergens . CLEC18A has also been implicated in mixed cryoglobulinemia (MC), a condition associated with hepatitis C virus infection, by impairing phagocytosis through the reduction of FcγRIIA expression .

What detection methods are available for CLEC18A in research samples?

CLEC18A can be detected using multiple methodological approaches:

• Western Blotting: Samples containing approximately 1 × 10^6 cells should be lysed with RIPA buffer and fractionated on 12% SDS-PAGE before transfer to PVDF membranes. Probing can be performed with anti-hCLEC18 monoclonal antibodies (such as clone 3A9E6) or anti-mCLEC18 antibodies (such as C8G), followed by appropriate secondary antibodies conjugated with horseradish peroxidase . Most commercially available antibodies demonstrate a detected molecular weight of 47-50 kDa .

• Flow Cytometry: For intracellular staining, cells should be fixed, permeabilized, and stained with fluorophore-conjugated anti-CLEC18A antibodies. Multi-parameter analysis can include surface markers like CD4, CD8, CD11b, Ly6G/Ly6C, and CD45R/B220 to identify specific cell populations expressing CLEC18A .

• Immunohistochemistry: Several antibodies are validated for IHC applications, particularly in human kidney and stomach tissues. Optimal results typically require antigen retrieval with TE buffer at pH 9.0, although citrate buffer at pH 6.0 may serve as an alternative .

• ELISA: Multiple antibody options are available for ELISA-based detection of CLEC18A in serum or cell culture supernatants .

The recommended dilutions vary by application, with Western blot typically using 1:500-1:1000, while IHC applications require 1:20-1:200 dilutions .

What are the species reactivity profiles of commonly available CLEC18A antibodies?

Commercially available CLEC18A antibodies demonstrate varied cross-reactivity profiles that researchers should consider when designing experiments:

• Most polyclonal CLEC18A antibodies show reactivity against human, mouse, and rat samples . This broad reactivity is advantageous for comparative studies across species.

• Some antibodies specifically target human CLEC18A with little to no cross-reactivity to mouse or rat proteins, which may be important for studies focused exclusively on human tissues or cells .

• When working with antibodies targeting specific amino acid sequences, such as AA 27-446 or AA 338-367, it is essential to verify the conservation of these sequences across species of interest .

The differential expression pattern of CLEC18A between humans and mice (ubiquitous in humans versus restricted to brain, kidney, and heart in mice) makes cross-species comparisons particularly relevant but potentially challenging . Researchers should validate species reactivity in their specific experimental systems, as reactivity may be dependent on the specific application method.

How does CLEC18A's role as a TLR3 co-receptor affect experimental design for viral immunity studies?

When designing experiments to investigate CLEC18A's function in viral immunity, researchers should consider several critical factors based on its role as a TLR3 co-receptor:

• Co-receptor Complex Formation: CLEC18A associates with TLR3 in endosomes and enhances binding affinity to poly(I:C). Experimental designs should incorporate co-immunoprecipitation assays to verify complex formation between CLEC18A and TLR3 under various stimulation conditions .

• Binding Affinity Analysis: Studies have demonstrated that compared to TLR3 alone, TLR3-CLEC18A and TLR3-CLEC18A(S339R) complexes show increased binding affinity to poly(I:C). Surface plasmon resonance or similar binding assays should be included to quantify these differences in binding kinetics .

• Interferon Production Profiling: CLEC18A selectively enhances production of type I and type III interferons without significantly affecting proinflammatory cytokines. Experimental protocols should include comprehensive cytokine panels measuring IFN-α, IFN-β, and IFN-λ2/3, alongside proinflammatory cytokines like TNF-α, CCL2, and CCL5 to capture this differential response .

• Viral Challenge Models: ROSA-CLEC18A and ROSA-CLEC18A(S339R) mice demonstrate enhanced resistance to H5N1 IAV infection compared to wild-type mice. In vivo infection models should monitor viral titers, body weight changes, survival rates, and pulmonary inflammation parameters to fully assess CLEC18A's protective effects .

• Temporal Dynamics: The interferon response shows distinct temporal patterns, with higher levels of IFN-λ2/3 observed on day 4 but not day 7 post-infection. Time-course experiments are essential to capture these dynamics properly .

What are the critical considerations when using CLEC18A antibodies for investigating its role in phagocytosis?

CLEC18A has been identified as a negative regulator of phagocytosis, particularly through its effect on FcγRIIA expression. When designing experiments to investigate this function, researchers should consider:

• Neutralization Approaches: Treatment of human neutrophils with anti-CLEC18A antibodies (10 μg/mL) can neutralize the effects of exogenous CLEC18A (40 ng/mL) . Experimental design should include appropriate antibody controls to distinguish blocking effects from potential Fc-mediated effects.

• Mechanism Characterization: CLEC18A inhibits FcγRIIA expression through NOX-2-dependent reactive oxygen species production. Experiments should incorporate ROS detection methods and NOX-2 inhibitors to confirm this mechanistic pathway .

• Endosomal Trafficking Analysis: Since CLEC18A interacts with Rab5 and Rab7, confocal microscopy with co-localization analysis should be employed to track these interactions in real-time during phagocytosis .

• Autophagosome Maturation: CLEC18A affects autophagosome-lysosome fusion by reducing Rab7 recruitment to autophagosomes. Experimental designs should include autophagy flux assays and markers like LC3, ATG5, and p62 to monitor these processes .

• Clinical Correlation Analysis: In HCV patients, particularly those with mixed cryoglobulinemia, decreased levels of FcγRIIA correlate with CLEC18A expression. Study designs should include patient stratification based on CLEC18A levels and cryoglobulin status to properly interpret functional data .

How can the S339R mutation in CLEC18A be utilized in comparative functional studies?

The S339R mutation in the CTLD domain of CLEC18A presents a valuable tool for comparative functional studies:

• Enhanced Antiviral Activity: CLEC18A(S339R) shows greater potency than wild-type CLEC18A in protecting mice from H5N1 IAV-induced body weight loss and lethality. Comparative studies should include both variants to quantify this functional difference .

• Binding Specificity Analysis: The single amino acid change profoundly affects binding to polysaccharides and house dust mite allergens. Binding assays with diverse ligands should be performed to characterize the differential binding profiles of wild-type and mutant proteins .

• TLR3 Co-receptor Function: Both CLEC18A and CLEC18A(S339R) enhance poly(I:C) binding when complexed with TLR3, but potential differences in signal transduction efficiency may exist. Signaling pathway analysis focusing on IRF3 and IRF7 activation should be included .

• In vivo Modeling: ROSA-CLEC18A and ROSA-CLEC18A(S339R) transgenic mice provide powerful models for comparative studies. Experimental designs should include both genotypes alongside wild-type controls when assessing viral clearance, cytokine responses, and pulmonary inflammation .

• Structure-Function Relationship: Molecular modeling and structural analyses can help elucidate how this single amino acid substitution affects the protein's conformation and binding pocket characteristics .

What are the optimal conditions for detecting CLEC18A in different human and mouse tissues?

When designing experiments to detect CLEC18A across different tissues, researchers should consider tissue-specific expression patterns and optimal detection methods:

• Human Tissues:

  • Myeloid cells and liver tissue show the highest expression levels in humans .

  • For Western blot analysis, approximately 1 × 10^6 cells should be processed with RIPA buffer for optimal protein extraction .

  • For immunohistochemistry of human kidney and stomach tissues, antigen retrieval with TE buffer at pH 9.0 is recommended, with antibody dilutions of 1:20-1:200 .

• Mouse Tissues:

  • Brain, kidney, and heart tissues show significant expression in mice .

  • Flow cytometry with intracellular staining protocols is effective for detecting CLEC18A in mouse immune cells, using appropriate surface markers to identify specific populations .

  • Anti-mCLEC18 monoclonal antibodies like clone C8G are recommended for Western blotting of mouse tissues .

• Application-Specific Considerations:

  • For Western blotting, the expected molecular weight range is 47-50 kDa .

  • For ELISA applications, biotinylated or HRP-conjugated antibodies may provide enhanced sensitivity .

  • For immunofluorescence applications, FITC-conjugated antibodies are available and effective .

How should researchers design experiments to investigate CLEC18A's dual role in viral defense and autoimmunity?

CLEC18A exhibits a complex dual role in enhancing antiviral responses while potentially contributing to autoimmune manifestations like mixed cryoglobulinemia. Experimental designs addressing this duality should:

• Model Selection:

  • For viral defense studies, both in vitro cell systems (using poly(I:C) stimulation or direct viral infection) and in vivo models (such as H5N1 IAV infection in ROSA-CLEC18A mice) are appropriate .

  • For autoimmunity aspects, HCV infection models or patient-derived samples stratified by cryoglobulinemia status provide relevant contexts .

• Pathway Dissection:

  • Type I/III interferon induction pathways should be monitored alongside mechanisms affecting FcγRIIA expression and phagocytosis .

  • The NOX-2-dependent ROS production pathway should be specifically examined in relation to FcγRIIA downregulation .

• Temporal Considerations:

  • Acute vs. chronic effects should be distinguished, as CLEC18A may initially enhance antiviral responses while potentially contributing to autoimmunity in chronic settings .

  • Time-course experiments tracking CLEC18A expression, viral load, and immune complex clearance are crucial .

• Therapeutic Response Monitoring:

  • Changes in CLEC18A levels following direct-acting antiviral therapy correlate with reduced HCV RNA titers and diminished cryoglobulin levels, suggesting utility as a biomarker .

  • Experimental designs should include pre- and post-treatment time points to capture these dynamics.

What controls and validation steps are essential when using CLEC18A antibodies in research?

When employing CLEC18A antibodies in research, the following controls and validation steps are essential:

• Antibody Specificity Validation:

  • Western blotting against recombinant CLEC18A protein (full-length or specific domains) to confirm target recognition.

  • Competitive binding assays using recombinant CLEC18A to confirm specific staining in flow cytometry or immunohistochemistry.

  • CLEC18A knockdown or knockout samples as negative controls to verify signal specificity .

• Application-Specific Controls:

  • For Western blotting: Loading controls (β-actin, GAPDH), molecular weight markers to confirm the expected 47-50 kDa band, and isotype control antibodies .

  • For immunohistochemistry: Isotype controls, blocking peptide controls, and tissue samples known to be negative for CLEC18A expression .

  • For flow cytometry: Fluorescence-minus-one (FMO) controls, isotype controls, and dead cell exclusion dyes .

• Cross-Reactivity Assessment:

  • Testing antibodies against tissues from multiple species (human, mouse, rat) to confirm the reported cross-reactivity profile .

  • For studies comparing human and mouse CLEC18A, validation of antibody performance in both species is crucial given their different expression patterns .

• Functional Validation:

  • Confirming that antibody binding does not interfere with the functional activity being studied, or deliberately using neutralizing antibodies when inhibition is desired .

  • Including positive controls that demonstrate the expected biological response, such as enhanced interferon production or altered phagocytosis .

What are common technical challenges when detecting CLEC18A and how can they be addressed?

Researchers working with CLEC18A antibodies may encounter several technical challenges:

• Variable Expression Levels:

  • Challenge: Expression levels vary significantly between tissues and species, with human myeloid cells and liver showing high expression while mouse expression is limited to brain, kidney, and heart .

  • Solution: Optimize protein loading (10-30 μg total protein) for Western blotting and use signal amplification methods like biotin-streptavidin systems for low-expressing tissues .

• Background Signal:

  • Challenge: High background, particularly in immunohistochemistry applications.

  • Solution: Optimize blocking conditions (5% BSA or normal serum from the secondary antibody species), increase washing steps, and titrate primary antibody (starting with 1:20-1:200 for IHC) .

• Epitope Accessibility:

  • Challenge: Poor signal in fixed tissue samples.

  • Solution: Compare multiple antigen retrieval methods; while TE buffer at pH 9.0 is generally recommended, citrate buffer at pH 6.0 may be more effective for certain tissues or fixation conditions .

• Species Cross-Reactivity Issues:

  • Challenge: Unexpected cross-reactivity or lack of reactivity in comparative studies.

  • Solution: Validate antibody performance in each species before comparative analysis, using appropriate positive controls .

• Detection in Complex Samples:

  • Challenge: Difficulty detecting CLEC18A in clinical samples with multiple interfering factors.

  • Solution: Consider immunoprecipitation before Western blotting or use sensitive ELISA methods with pre-clearing steps .

How can researchers effectively use CLEC18A antibodies to investigate its endosomal localization and trafficking?

CLEC18A localizes to endosomal compartments and interacts with Rab5 and Rab7, key regulators of endosomal trafficking. To effectively study these properties:

• Co-localization Studies:

  • Implement dual or triple immunofluorescence staining with antibodies against CLEC18A, TLR3, and endosomal markers (Rab5 for early endosomes, Rab7 for late endosomes) .

  • Use confocal microscopy with Z-stack imaging to capture three-dimensional co-localization data.

  • Quantify co-localization using Pearson's or Mander's correlation coefficients.

• Live Cell Imaging:

  • Utilize GFP-tagged CLEC18A constructs alongside fluorescently labeled endosomal markers for real-time trafficking analysis .

  • Implement pulse-chase experiments with fluorescently labeled ligands to track CLEC18A-mediated endocytosis.

• Subcellular Fractionation:

  • Employ differential centrifugation to isolate endosomal fractions followed by Western blotting for CLEC18A and endosomal markers .

  • Use density gradient fractionation for higher resolution separation of early and late endosomal compartments.

• Functional Trafficking Assays:

  • Implement endosomal pH sensitivity assays using pH-sensitive fluorophores to track CLEC18A trafficking through acidifying compartments.

  • Use dominant-negative Rab constructs to disrupt specific trafficking steps and assess effects on CLEC18A localization and function .

• Autophagosome-Lysosome Fusion Analysis:

  • Since CLEC18A affects Rab7 recruitment to autophagosomes, implement tandem fluorescent-tagged LC3 (mRFP-GFP-LC3) assays to monitor autophagosome maturation .

  • Use lysosomal inhibitors (Bafilomycin A1) in conjunction with CLEC18A overexpression to dissect its effects on the autophagy pathway.

What methodological approaches can distinguish between CLEC18A's effects on phagocytosis versus its antiviral functions?

CLEC18A exhibits distinct roles in enhancing antiviral responses while simultaneously impairing phagocytosis. To methodologically separate these functions:

• Domain-Specific Mutants:

  • Generate domain-specific mutants or truncated versions of CLEC18A to identify regions responsible for TLR3 interaction versus those affecting FcγRIIA expression .

  • Test these constructs in parallel antiviral assays (interferon production) and phagocytosis assays to determine domain-specific functions.

• Pathway-Specific Inhibitors:

  • Use NOX-2 inhibitors to specifically block the ROS-dependent pathway through which CLEC18A impairs phagocytosis without affecting its TLR3 co-receptor function .

  • Apply TLR3 signaling inhibitors to distinguish direct effects on phagocytosis from indirect effects via altered cytokine production.

• Cell Type-Specific Analyses:

  • Implement parallel experiments in hepatocytes (focusing on antiviral functions) and phagocytes like neutrophils (focusing on immune complex clearance) .

  • Use cell-type specific promoters for CLEC18A expression in transgenic models to separate tissue-specific effects.

• Temporal Dissection:

  • Conduct time-course experiments to distinguish immediate CLEC18A effects (typically antiviral) from delayed effects (typically immunomodulatory) .

  • Implement inducible expression systems to control CLEC18A expression at different stages of infection or immune challenge.

• Ligand-Specific Approaches:

  • Use poly(I:C) to specifically trigger the TLR3-dependent pathway versus immune complexes to activate FcγR-dependent phagocytosis .

  • Implement competitive binding assays to determine if CLEC18A's interaction with different ligands produces distinct functional outcomes.

How can CLEC18A antibodies be utilized to explore its potential as a biomarker for viral infections and autoimmune conditions?

Recent research suggests CLEC18A may serve as a valuable biomarker in several clinical contexts:

• HCV-Associated Mixed Cryoglobulinemia:

  • CLEC18A levels correlate positively with cryoglobulin levels in patients with HCV-associated MC (r = 0.43, P < 0.05) .

  • Sequential monitoring of CLEC18A in serum samples before and after direct-acting antiviral therapy shows decreasing trends that parallel reduced HCV RNA titers and diminished cryoglobulin levels .

  • Implement standardized ELISA protocols for clinical sample testing and establish reference ranges across different disease states.

• Viral Infection Monitoring:

  • Similar to findings with hepatitis B virus infection stages , CLEC18A may serve as a stage-specific marker for other viral infections.

  • Develop multiplex assays combining CLEC18A with established viral markers for improved prognostic value.

  • Correlate CLEC18A levels with treatment responses and clinical outcomes to validate its predictive potential.

• Assay Development Considerations:

  • Establish standardized sample collection and processing protocols to minimize pre-analytical variability.

  • Determine the stability of CLEC18A in various sample types (serum, plasma, tissue) under different storage conditions.

  • Develop reference materials and calibrators for inter-laboratory standardization of CLEC18A quantification.

• Differential Diagnosis Applications:

  • Investigate CLEC18A as part of biomarker panels to distinguish between viral infections and autoimmune conditions with similar presentations.

  • Explore tissue-specific expression patterns as potential indicators of organ-specific pathologies.

What are emerging areas of CLEC18A research where antibody-based approaches will be critical?

Several emerging research directions will rely heavily on antibody-based approaches:

• CLEC18A in Additional Viral Infections:

  • Beyond influenza and hepatitis viruses, CLEC18A's role in other viral infections (particularly RNA viruses that engage TLR3) remains to be explored .

  • Neutralizing antibodies will be essential tools for mechanistic studies in these new viral contexts.

  • Development of antibodies recognizing viral-specific conformational changes in CLEC18A may provide insights into context-dependent functions.

• Regulation of Autophagy:

  • CLEC18A's interaction with Rab7 and its effects on autophagosome maturation represent an emerging area of interest .

  • Antibodies targeting specific domains involved in Rab7 interaction will be critical for dissecting this function.

  • Phospho-specific antibodies may help identify regulatory modifications affecting CLEC18A's role in autophagy.

• Structural Studies:

  • The significant functional impact of the S339R mutation highlights the importance of structure-function relationships in CLEC18A .

  • Antibodies recognizing specific conformational states may facilitate crystallization efforts and structural analyses.

  • Epitope-specific antibodies could help map functional domains and interaction surfaces.

• Therapeutic Applications:

  • As understanding of CLEC18A's dual role in immunity and autoimmunity advances, therapeutic antibodies may be developed to modulate its activity .

  • Function-blocking antibodies targeting specific domains could potentially enhance antiviral functions while minimizing autoimmune effects.

  • Antibody-based imaging approaches may help track CLEC18A expression in vivo during disease progression and treatment.

How do differences between human and mouse CLEC18A affect experimental design and interpretation of results?

The significant differences between human and mouse CLEC18A create important considerations for experimental design and data interpretation:

• Expression Pattern Differences:

  • Human CLEC18A is ubiquitously expressed with highest levels in myeloid cells and liver, while mouse CLEC18A is restricted to brain, kidney, and heart .

  • This fundamental difference necessitates careful selection of experimental systems; findings in mouse models may not directly translate to human biology.

  • Cell type-specific analyses using flow cytometry with appropriate surface markers are essential when comparing across species .

• Functional Response Variations:

  • CLEC18A may contribute to differential immune responses to poly(I:C) and IAV infection between humans and mice .

  • Experiments should include both species when possible, or utilize transgenic mice expressing human CLEC18A (like ROSA-CLEC18A models) .

  • Cross-species comparisons should always include appropriate controls to account for species-specific differences in baseline responses.

• Antibody Selection Considerations:

  • When designing comparative studies, select antibodies validated for both species or use species-specific antibodies in parallel .

  • For flow cytometry applications in mouse samples, home-made antibody clone C5F (Alexa Fluor 647-conjugated) has been validated for intracellular staining .

  • For Western blotting of mouse samples, anti-mCLEC18 mAb (clone C8G) is recommended .

• Translation of Findings:

  • The protective effect of CLEC18A against H5N1 IAV infection observed in ROSA-CLEC18A and ROSA-CLEC18A(S339R) mice suggests potential evolutionary advantages of human CLEC18A expression patterns .

  • When interpreting results, consider whether observed effects reflect conserved functions or species-specific adaptations.

  • Humanized mouse models may provide valuable intermediate systems for translational studies.